U.S. markets open in 3 hours 14 minutes

Enochian Biosciences, Inc. (ENOB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9300+0.1100 (+6.04%)
At close: 04:00PM EDT
1.8400 -0.09 (-4.66%)
After hours: 06:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close1.8200
Bid0.7500 x 800
Ask1.9600 x 800
Day's Range1.7900 - 1.9600
52 Week Range1.4200 - 13.7800
Avg. Volume95,987
Market Cap102.193M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-0.7890
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ENOB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Enochian Biosciences, Inc.
    RGNX: Lowering target price to $25.00REGENXBIO INC has an Investment Rating of HOLD; a target price of $25.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • Simply Wall St.

    Enochian Biosciences, Inc. (NASDAQ:ENOB) insiders have significant skin in the game with 49% ownership

    Every investor in Enochian Biosciences, Inc. ( NASDAQ:ENOB ) should be aware of the most powerful shareholder groups...

  • GlobeNewswire

    Enochian BioSciences Appoints Dr. Richard Whitley As Senior Scientific Advisor

    LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Today, Enochian BioSciences (the Company) announced that Dr. Richard (Rich) Whitley, M.D., of the University of Alabama at Birmingham (UAB), will become the Company’s Senior Scientific Advisor. A Distinguished Professor of Pediatrics at UAB, Dr. Whitley brings decades of virology research experience to the Company, including clinical research experience to develop antiviral therapies. "We are incredibly excited to bring on Dr. Whitley

  • GlobeNewswire

    Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data

    LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and investors a clear understanding of the Company’s pipelines. The results of this investigation verified key primary data for the Company’s HIV and cancer pipelines. The investigation also verified the primary data from an animal model with intravenous delivery of a potential treatment for COVID-19 that was